15 results about "Sudden death" patented technology

A new blood assay is provided which identifies patients who develop hemorrhage after revascularization therapy based on temporal kinetics of free serum iron levels. This approach overcomes the limitations of gold-standard clinical practice of performing cardiac magnetic resonance imaging, as the latter is not always accessible due to poor availability and a high cost. The blood assay can be a new diagnostic approach to broadly permit classification of myocardial infarction based on hemorrhage status, and to allow for suitable management of hemorrhagic patients, who would otherwise carry a significant risk for heart failure and sudden death.

This application discloses a method, device, storage medium, and equipment for predicting the risk of sudden cardiac death due to arrhythmia, relating to the field of biomedical technology. The method includes: acquiring multi-channel cardiac magnetic signals from a subject; performing fidelity enhancement processing on the multi-channel cardiac magnetic signals to extract core features characterizing the cardiac magnetic field; constructing a topological geometric model of the cardiac fiber plexus; extracting topological invariants of the cardiac electrical conduction system based on the core features and the topological geometric model; conducting non-equilibrium phase transition dynamics detection on the topological geometric model of the cardiac fiber plexus to obtain phase transition features reflecting the stability of the cardiac electrical conduction system; inputting the topological invariants and phase transition features into a preset topological neural network to complete a quantitative analysis of the degree of chaos in the cardiac electrical conduction system; and generating a risk score and early warning indicators for sudden cardiac death due to arrhythmia based on the quantitative analysis results. This application can achieve accurate early warning of the risk of sudden cardiac death due to arrhythmia.

The invention discloses a sudden cardiac death risk prediction method, device and system and a storage medium, and the method comprises the steps: obtaining resting electrocardio data outputted through a plurality of electrocardiogram leads, processing the resting electrocardio data to obtain high-frequency QRS wave group data corresponding to each electrocardiogram lead, and obtaining high-frequency QRS features corresponding to each electrocardiogram lead; determining a lead positive index corresponding to each electrocardiogram lead according to the high-frequency form index corresponding to each electrocardiogram lead; determining whether there is a sudden cardiac death risk based on at least one of a plurality of conditions; and under the condition of determining that the sudden cardiac death risk exists, predicting the sudden cardiac death risk level according to the sum value of the high-frequency form indexes corresponding to the electrocardiogram leads. According to the scheme provided by the embodiment of the invention, the sudden death risk is quantified based on a plurality of (greater than or equal to 12) lead high-frequency form indexes and values reflecting the myocardial injury volume under the qualitative condition of a plurality of risk factors, and the missed diagnosis rate and accuracy can be taken into account.

Processes are provided based on an interventional (device-based) approach to minimize the development of intramyocardial hemorrhage within the myocardial infarction (MI) zone. In one exemplary process, the revascularization occurs in an incremental fashion prior to fully opening the vessel, so as to modulate the hydrostatic pressure transmitted from the proximal end of the catheter, prior to placing a stent. In another exemplary process, the stent will be placed within the central core of the embolization and will slowly expand within the lumen reaching full patency over a period of time. Devices operated with these processes can also greatly reduce the chance of development of intramyocardial hemorrhage with the MI zone. These developments can improve the outcome in hemorrhagic patients, who otherwise carry a significant risk for heart failure and sudden death.

The invention discloses an imidazole derivative as shown in a formula (I), or a salt, a stereoisomer or a nitrogen oxide thereof, and R and R1 are defined in the description. The compound shown in the formula (I) can be used as a reagent for killing harmful microorganisms, and especially has a good effect on fungi causing damping-off.

The invention discloses a cardiac ion channel disease detection primer group and application thereof. The microfluidic chip and the multi-gene risk assessment model are combined, so that the risk of the cardiac ion channel disease can be assessed for potential patient groups, risk early warning is provided for the potential risk groups, the risk groups are guided to perform medical diagnosis and treatment, the risk of diseases or sudden death caused by the ion channel disease is reduced, and the application prospect is wide.

A system for the prevention of a sudden death syndrome in a user includes a galvanic vestibular stimulator and an audio vestibular stimulator. The system is used in a method for preventing permanent breathing arrest in a user susceptible to a sudden death syndrome by stimulating a vestibular system of the user via at least one of electrical galvanic vestibular stimulation and sound-induced vestibular stimulation using bone conduction.

Disclosed are a sudden cardiac death risk prediction method, device, system and storage medium. The method comprises: acquiring resting electrocardiogram data output through a plurality of electrocardiogram leads, processing the resting electrocardiogram data to obtain high-frequency QRS complex data corresponding to each electrocardiogram lead, and obtaining high-frequency QRS features corresponding to each electrocardiogram lead according to the high-frequency QRS complex data; determining a lead positive index corresponding to each electrocardiogram lead according to a high-frequency morphology index corresponding to each electrocardiogram lead; determining whether there is a sudden cardiac death risk based on at least one of a plurality of conditions; and in the case of determining that there is a sudden cardiac death risk, predicting a sudden cardiac death risk level according to a sum of the high-frequency morphology indexes corresponding to each electrocardiogram lead. The scheme provided in the embodiments of the present application can quantitatively predict the sudden death risk based on the sum of the high-frequency morphology indexes of a plurality of (greater than or equal to 12) leads reflecting the myocardial injury volume in the case of qualitative determination based on a plurality of risk factors, and can take into account the misdiagnosis rate and accuracy.

The invention discloses application of a reagent for detecting SCN2B and / or SCN4B gene mutation in preparation of a hereditary arrhythmia detection product. According to the present invention, through the dual detection system combining whole exon sequencing with Sanger sequencing verification, the accurate capture of the pathogenic mutation such as SCN2B-R28Q / Y69H / P210L and SCN4B-T211M is achieved, and the problem that only SCN5A is determined as the main pathogenic gene in the clinical diagnosis of J wave syndrome (JWS) at present, and the gene detection of about 70-80% of patients is negative is solved. Wherein the three missense mutations of the SCN2B and the SCN4B-T211M variation are reported in the JWS for the first time, and the SCN4B is clear as the JWS pathogenic gene for the first time, so that the pathogenic gene spectrum of the JWS is obviously expanded. A detection product developed on the basis of the method can realize early accurate diagnosis, provide personalized risk assessment (such as sudden death early warning induced by fever) for patients, guide genetic screening of family members and remarkably improve clinical diagnosis and treatment efficiency.

The application discloses application of a reagent for detecting SCN2B and / or SCN4B gene mutation in preparation of a genetic arrhythmia detection product. Through a double detection system of whole exon sequencing combined with Sanger sequencing verification, the application realizes accurate capture of pathogenic mutations such as SCN2B-R28Q / Y69H / P210L and SCN4B-T211M, and solves the difficulty that only SCN5A is confirmed as a main pathogenic gene in the current clinical diagnosis of J wave syndrome (JWS), and about 70%-80% of patients have gene detection negative. The three missense mutations of SCN2B and the SCN4B-T211M variation are reported for the first time in JWS, and SCN4B is confirmed as a pathogenic gene of JWS for the first time, which significantly expands the pathogenic gene spectrum of JWS. The detection product developed based on this can realize early accurate diagnosis, provide personalized risk assessment (such as early warning of sudden death induced by fever) for patients, and guide genetic screening of family members, and significantly improves the clinical diagnosis and treatment efficiency.

The invention relates to a method for establishing an electrocardiosignal real-time sequence prediction system, which comprises the following steps of: modeling a complex relationship among lead measuring points, and learning a complex time dynamic relationship among operation data and states of 32 measuring points with the highest electric signal conduction correlation degree between a specific structure and cells in the heart of a patient; the accurate prediction of the cardiac activity key electric signal parameters of the specified measuring point in a certain time period in the future is very important for finding risks such as potential arrhythmia, preventing sudden myocardial infarction death and ensuring the health state of a patient. The trained long-short-term memory network model is deployed in clinical application, continuous learning and updating can be carried out according to new real-time data to adapt to evolution and change of the system, and compared with manual operation possibly affected by subjective judgment, fatigue and errors, the prediction system provided by the invention carries out prediction based on historical data, and the prediction efficiency is greatly improved. The method has the advantages of short time consumption and high efficiency, and reduces the influence of subjective factors on the prediction result, thereby reducing the potential risk of human errors.

Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.

The application provides a biomarker combination specific to coronary sudden death and application and products thereof, and belongs to the technical field of forensic science.The biomarker combination comprises ascorbic acid, docosahexaenoic acid, carnitine, glutamine and norleucine.The biomarker combination is significantly changed in serum samples of individuals with coronary sudden death, and after ROC verification, shows good diagnostic performance, indicating that it has the potential to be applied to forensic identification of coronary sudden death.The potential application value of the non-targeted metabolomics strategy of the application in difficult and complex death cause identification provides a new idea for molecular diagnosis of death cause investigation.

This invention relates to a management platform and its implementation path for elderly atrial fibrillation (AF) patients in rural areas, primarily aimed at addressing the heavy management burden and uneven distribution of medical services for AF patients. AF has high disability and mortality rates, increasing the risk of stroke, heart failure, and sudden death, especially in the rapidly aging rural areas of Chengdu, where the management burden is particularly prominent. This invention achieves this through the following technical solutions: First, it conducts routine opportunistic screening for AF based on government-led rural public health check-up programs, incorporating diagnosed patients into digital grid management units; second, it creates digital data on high-risk AF patients, achieving grid-based and information-based management; the expected results include realizing a digital grid-based AF management cloud platform for "decision sharing" between doctors and patients, standardizing the comprehensive management of AF patients in rural areas, forming a theoretical framework for a "rural elderly AF management model" with Chengdu characteristics, and providing a scientific basis for policy formulation.

The invention relates to the technical field of electrocardiogram monitoring edge calculation, in particular to an edge calculation-based exercise electrocardiogram real-time analysis and sudden death risk early warning system, which comprises a signal preprocessing module for completing exercise electrocardiogram signal acquisition and preprocessing, and a feature extraction module for extracting time domain and heart rate variability features to form a feature set; the edge reasoning module outputs a real-time cardiac function state score at an edge computing node through a lightweight model, and the risk early warning module judges a malignant arrhythmia precursor in combination with a preset threshold value. And if the precursor exists, the state inversion module reconstructs a physiological event sequence by relying on the electrocardiogram historical signal and the characteristic time sequence change, and the early warning generation module locates a risk starting moment and a leading inducement and generates an early warning log with a timestamp and an event type. According to the method, the real-time analysis of the exercise electrocardiogram edge end is realized, the risk precursor traceability early warning is completed, and the requirements of exercise scene electrocardiogram monitoring and sudden death risk early warning are met.